KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - Deferred ChargesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Gsk (GSK) Revenue (2016 - 2026)

Gsk has reported Revenue over the past 18 years, most recently at $10.3 billion for Q1 2026.

  • For Q1 2026, Revenue rose 8.65% year-over-year to $10.3 billion; the TTM value through Mar 2026 reached $43.9 billion, down 11.06%, while the annual FY2025 figure was $43.5 billion, 7.9% up from the prior year.
  • Revenue for Q1 2026 was $10.3 billion at Gsk, down from $11.5 billion in the prior quarter.
  • Over five years, Revenue peaked at $19.6 billion in Q4 2024 and troughed at $8.4 billion in Q1 2023.
  • A 5-year average of $11.3 billion and a median of $10.3 billion in 2026 define the central range for Revenue.
  • On a YoY basis, Revenue climbed as much as 35.73% in 2022 and fell as far as 50.25% in 2022.
  • Year by year, Revenue stood at $16.6 billion in 2022, then increased by 5.89% to $17.5 billion in 2023, then grew by 11.59% to $19.6 billion in 2024, then crashed by 41.42% to $11.5 billion in 2025, then fell by 10.28% to $10.3 billion in 2026.
  • Business Quant data shows Revenue for GSK at $10.3 billion in Q1 2026, $11.5 billion in Q4 2025, and $11.5 billion in Q3 2025.